Eli Lilly has struck a $5.9 billion deal to partner with Stipple Bio on oncology drug candidates that more precisely target tumor cells.
Founded by Fred Hutch Cancer Center’s Aaron Ring, M.D., Ph.D., and University of California, San Francisco’s Aashish Manglik, M.D., Ph.D., Stipple is built on its Pointillist platform for discovering cell-surface epitopes specific to cancer cells. By operating on the level of epitopes, the biotech aims to develop medicines that are highly specific for tumor cells, avoiding the on-target, off-tumor toxicity that limits the safety and efficacy of many therapeutics.
Lilly is making an upfront payment and an equity investment in Stipple, although neither party has broken down the financials in their announcement. The pact features research, development and commercialization milestones that could swell the value of the partnership to $5.9 billion, plus tiered royalties.
In return, Lilly has gained exclusive worldwide rights to develop and commercialize products arising from its multi-target collaboration with Stipple. The alliance covers multiple, undisclosed modalities and indications that are yet to be determined. Stipple’s internal pipeline features antibody-drug conjugates and T-cell engagers for treating solid tumors, including pancreatic cancer.
To advance the pipeline, Stipple raised a $100 million series A round in April. RA Capital, a16z Bio+Health and Nextech Invest co-led the round, giving Stipple a cash runway that extends into 2029. By then, the biotech aims to have started multiple early-stage trials of its lead candidate, STP-100, and have identified additional tumor-specific cell-surface epitopes to unlock further pipeline programs.
Investors have bet that Stipple can expand the set of druggable cancer targets. Drugs typically target surface proteins, such as HER2, which are overexpressed on tumor cells and found at low levels in healthy tissues. Such drugs can cause on-target, off-tumor toxicities that limit dosing and, by extension, efficacy. Targeting epitopes that are specific to cancer cells could bypass the barrier to higher doses.
Lilly’s interest in the platform has driven the drugmaker to ink yet another deal. Over the past six weeks, Lilly has struck an $870 million expansion to its Gate Bioscience alliance, committed up to $1.1 billion to partner with Metis TechBio and agreed to buy Calytrix Bio on Monday for up to $1.5 billion.